[1]李垄英,王启平,黄 慧.唑来膦酸、化疗联合多维度协同管理治疗非小细胞肺癌骨转移的疗效及对患者疼痛程度和生活质量的影响[J].医学信息,2022,35(21):98-100.[doi:10.3969/j.issn.1006-1959.2022.21.023]
 LI Long-ying,WANG Qi-ping,HUANG Hui.Efficacy of Zoledronic Acid and Chemotherapy Combined with Multidimensional Collaborative Management in the Treatment of Bone Metastasis of Non-small Cell Lung Cancer and its Effect on Pain Degree and Quality of Life[J].Journal of Medical Information,2022,35(21):98-100.[doi:10.3969/j.issn.1006-1959.2022.21.023]
点击复制

唑来膦酸、化疗联合多维度协同管理治疗非小细胞肺癌骨转移的疗效及对患者疼痛程度和生活质量的影响()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年21期
页码:
98-100
栏目:
临床研究
出版日期:
2022-11-01

文章信息/Info

Title:
Efficacy of Zoledronic Acid and Chemotherapy Combined with Multidimensional Collaborative Management in the Treatment of Bone Metastasis of Non-small Cell Lung Cancer and its Effect on Pain Degree and Quality of Life
文章编号:
1006-1959(2022)21-0095-03
作者:
李垄英王启平黄 慧
(大余县人民医院肿瘤内科,江西 大余 341500)
Author(s):
LI Long-yingWANG Qi-pingHUANG Hui
(Department of Oncology,Dayu County People’s Hospital,Dayu 341500,Jiangxi,China)
关键词:
唑来膦酸多维度协同管理非小细胞肺癌骨转移疼痛程度生活质量
Keywords:
Zoledronic acidMulti-dimensional collaborative managementNon-small cell lung carcinomaBone metastasisPain degreeQuality of life
分类号:
R734.2
DOI:
10.3969/j.issn.1006-1959.2022.21.023
文献标志码:
A
摘要:
目的 研究唑来膦酸、化疗联合多维度协同管理治疗非小细胞肺癌骨转移疗效及疼痛程度和生活质量影响。方法 选取2019年6月-2022年7月在我院诊治的78例非小细胞肺癌骨转移患者为研究对象,采用随机数字表法分为对照组和观察组,各组39例。对照组采用化疗联合多维度协同管理,观察组在对照组基础上给予唑来膦酸治疗,比较两组临床疗效、疼痛程度、心理状况、生活质量及不良反应发生情况。结果 观察组总有效率为76.92%,高于对照组的56.41%(P<0.05);观察组0级、Ⅰ级疼痛程度占比均高于对照组,Ⅱ级、Ⅲ级均低于对照组(P<0.05);两组焦虑、抑郁评分均低于治疗前,生活质量量表各维度评分均高于治疗前,且观察组焦虑、抑郁评分低于对照组,生活质量量表各维度评分高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论 唑来膦酸、化疗联合多维度协同管理治疗非小细胞肺癌骨转移效果确切,可一定程度提高临床疗效,减轻患者疼痛程度,提高其生活质量水平,改善其心理状况,且不良反应少,具有较理想的有效性、安全性。
Abstract:
Objective To study the efficacy of zoledronic acid and chemotherapy combined with multi-dimensional collaborative management in the treatment of bone metastasis of non-small cell lung cancer and its influence on pain degree and quality of life.Methods A total of 78 patients with bone metastasis of non-small cell lung cancer diagnosed and treated in our hospital from June 2019 to July 2022 were selected as the research objects. They were divided into control group and observation group by random number table method, with 39 cases in each group. The control group was treated with chemotherapy combined with multidimensional collaborative management, and the observation group was treated with zoledronic acid on the basis of the control group. The clinical efficacy, pain degree, psychological status, quality of life and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 76.92%, which was higher than 56.41% of the control group (P<0.05). The proportion of grade 0 and grade Ⅰ pain in the observation group was higher than that in the control group, and grade Ⅱ and grade Ⅲ were lower than those in the control group (P<0.05). The scores of anxiety and depression in the two groups were lower than those before treatment, and the scores of each dimension of the quality of life scale were higher than those before treatment, and the scores of anxiety and depression in the observation group were lower than those in the control group, and the scores of each dimension of the quality of life scale were higher than those in the control group (P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Zoledronic acid, chemotherapy combined with multi-dimensional collaborative management is effective in the treatment of bone metastasis of non-small cell lung cancer, which can improve the clinical efficacy to a certain extent, reduce the pain of patients, improve their quality of life, improve their psychological status, and have fewer adverse reactions. It has ideal effectiveness and safety.

参考文献/References:

[1]王书航,王洁.2018年V3版NCCN非小细胞肺癌指南更新要点解读[J].华西医学,2018,33(4):388-392.[2]Himelstein AL,Foster JC,Khatcheressian JL,et al.Effect of longerinterval vs standard dosing of zoledronic acid on skeletal events inpatients with bone metastases: a randomized clinical trial[J].JAMA,2017,317(1):48-58.[3]陈滔,谭兴春.唑来膦酸联合化疗对非小细胞肺癌骨转移临床疗效及炎性因子水平的影响[J].药物评价研究,2019,42(6):163-166.[4]蒋桂成,林贵山,崔同建.姑息性放疗联合三阶梯止痛原则治疗非小细胞肺癌骨转移疼痛临床分析[J].肿瘤研究与临床,2018,30(12):851-854,859.[5]王伟.唑来膦酸对晚期非小细胞肺癌骨转移患者的疗效及VEGF-C和COX2水平的影响[J].医学临床研究,2019,36(4):640-642.[6]Qiu H,Yi T,Zhang L.Efficacy analysis of zoledronic acid combined with radiotherapy and combined with chemotherapy forbone metastasis of non-small cell lung cancer[J].Cancer Res,2017,29(7):437-441.[7]苏世先,刘前前,江美林,等.不同方案治疗肿瘤骨转移性疼痛的临床效果比较[J].实用癌症杂志,2017,31(10):1728-1730.[8]廖立潇,石大友,欧阳俊,等.沙利度胺联合地塞米松预防放射性肺炎的疗效分析[J].江西医药,2017,52(12):1352-1354.[9]周洋,邹华伟.唑来膦酸联合培美曲塞对肺腺癌细胞的体外抗肿瘤作用[J].山东医药,2017,56(1):35-37.[10]魏伟,张刚,杨明州,等.唑来膦酸联合苦参碱治疗晚期前列腺癌骨转移的疗效[J].国际泌尿系统杂志,2017,37(5): 646-648.[11]Andronis L,Goranitis I,Bayliss S,et al.Costeffectiveness of treatments for the management of bonemetastases: A systematic literature review[J].Pharmacoeconomics,2018,36(3):301-322.[12]杨志新,杨磊,钱阳晶.唑来膦酸对骨质疏松患者骨痛、骨密度和血清骨代谢标志物的影响[J].解放军医药杂志,2017,29(4):85-88.[13]梁坤,戴儒奇.89SrCl2联合唑来膦酸治疗前列腺癌骨转移的临床疗效与安全性观察[J].东南大学学报,2017,36(1):82-85.[14]宋亚琪,牛凤玲,林婷,等.唑来膦酸预防内分泌治疗所致绝经前乳腺癌患者骨丢失的作用[J].海南医学,2018,29(1):53-55.

相似文献/References:

[1]牟 婷,张朝阳.胰岛素联合唑来膦酸治疗糖尿病骨质疏松症对患者血清指标的影响[J].医学信息,2019,32(22):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
 MU Ting,ZHANG Chao-yang.Effect of Insulin Combined with Zoledronic Acid on Serum Markers in Patients with Diabetic Osteoporosis[J].Journal of Medical Information,2019,32(21):135.[doi:10.3969/j.issn.1006-1959.2019.22.045]
[2]李 博.唑来膦酸联合放疗治疗恶性肿瘤骨转移患者的效果[J].医学信息,2020,33(09):138.[doi:10.3969/j.issn.1006-1959.2020.09.044]
 YU Shou-jie,JIA Qian.The Effect of Zoledronic Acid Combined with Radiotherapy in Patients with Bone Metastases from Malignant TumorsLI Bo[J].Journal of Medical Information,2020,33(21):138.[doi:10.3969/j.issn.1006-1959.2020.09.044]
[3]黄应钟,杨立进.序贯抗骨质疏松对老年股骨粗隆间骨折愈合时间及再骨折的影响[J].医学信息,2021,34(18):94.[doi:10.3969/j.issn.1006-1959.2021.18.024]
 HUANG Ying-zhong,YANG Li-jin.The Effect of Sequential Anti-osteoporosis on the Healing Time ofIntertrochanteric Fracture and Re-fracture in the Elderly[J].Journal of Medical Information,2021,34(21):94.[doi:10.3969/j.issn.1006-1959.2021.18.024]
[4]朱道信,罗志环,陈少健,等.唑来膦酸联合骨化三醇对骨质疏松症患者骨密度及骨代谢相关指标的影响[J].医学信息,2021,34(23):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]
 ZHU Dao-xin,LUO Zhi-huan,CHEN Shao-jian,et al.Effect of Zoledronic Acid Combined with Calcitriol on Bone Mineral Density and Bone Metabolism in Patients with Osteoporosis[J].Journal of Medical Information,2021,34(21):162.[doi:10.3969/j.issn.1006-1959.2021.23.049]

更新日期/Last Update: 1900-01-01